This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jaffe, M. H. Articles by Paranjpe, M. Search for Related Content PubMed PubMed Citation Articles by Jaffe, M. H. Articles by Paranjpe, M. Social Bookmarking                            What's this?

Immunohistochemical and Clinical Evaluation of p53 in Canine Cutaneous Mast Cell Tumors

Departments of Veterinary Clinical Science (MHJ, ¹ GH, SCK, CSH, JRD) and Veterinary Pathology (HWT, MKL, MP), Louisiana State University School of Veterinary Medicine, Baton Route, LA; and Veterinary Diagnostic Assistance Laboratory (DMM), University of Georgia College of Veterinary Medicine, Athens, GA

One hundred twenty-six cutaneous mast cell tumors obtained by excisional biopsy from 106 dogs were evaluated using immunohistochemical staining for the presence of p53 protein. A standard avidin–biotin immunohistochemical protocol was used incorporating a polyclonal antibody of rabbit origin (CM-1) as the primary antibody. Histopathologic grading of tumors was performed on hemotoxylin and eosin–stained samples. There was a significant difference in the percentage of cells staining positive for p53 for the histopathologic grades (P = 0.0005). Grade III tumors had a significantly greater p53 content than did grade I or II tumors (P < 0.05). Clinical data obtained retrospectively was available for 54 dogs. Tumor recurred in 19 of 54 (35.2%) dogs. Twenty-nine dogs died by the end of the study; 9 of 29 (31.0%) died of mast cell tumor disease. Histopathologic grade showed a significant negative association with survival time. Both clinical stage and histopathologic grade showed a significant negative association with time to recurrence. The percentage of cells staining positive for p53 did not significantly improve the forward analysis. Immunohistochemical detection of p53 did not appear useful in characterizing the clinical association between cutaneous mast cell tumor cellular features and survival time or time to tumor recurrence in dogs.

Key words: Immunohistochemistry; mast cell tumor; p53.

Request reprints from Dr. Giselle Hosgood, Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803 (USA).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. M. Romansik, C. M. Reilly, P. H. Kass, P. F. Moore, and C. A. London Mitotic Index Is Predictive for Survival for Canine Cutaneous Mast Cell Tumors Vet. Pathol., May 1, 2007; 44(3): 335 - 341. [Abstract] [Full Text] [PDF]

				H. Wu, T. Hayashi, and M. Inoue Immunohistochemical Expression of p27 and p21 in Canine Cutaneous Mast Cell Tumors and Histiocytomas Vet. Pathol., May 1, 2004; 41(3): 296 - 299. [Abstract] [Full Text] [PDF]

				P. Loukopoulos, J. R. Thornton, and W. F. Robinson Clinical and Pathologic Relevance of p53 Index in Canine Osseous Tumors Vet. Pathol., May 1, 2003; 40(3): 237 - 248. [Abstract] [Full Text] [PDF]

				R. D. F. Strefezzi, J. G. Xavier, and J. L. Catao-Dias Morphometry of Canine Cutaneous Mast Cell Tumors Vet. Pathol., May 1, 2003; 40(3): 268 - 275. [Abstract] [Full Text] [PDF]

				K. Ozaki, T. Yamagami, K. Nomura, and I. Narama Mast Cell Tumors of the Gastrointestinal Tract in 39 Dogs Vet. Pathol., September 1, 2002; 39(5): 557 - 564. [Abstract] [Full Text] [PDF]